Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

January 03, 2023
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis

December 21, 2022
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

November 30, 2022
Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer

November 14, 2022
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 11, 2022
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

November 09, 2022
Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis

November 07, 2022
Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update

November 01, 2022
Chemomab Therapeutics to Present at Upcoming Scientific Conferences

October 28, 2022
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 12, 2022